基質金屬蛋白酶-1促進因子的基因多型性與中台灣前列腺癌患者的關係性
廖丞晞1,2,3,4、吳錫金5、張文馨2,3、蔡佳紋2,3、胡佩欣3,6、包大靝2,3
1國軍台中總醫院外科部泌尿外科 2中國醫藥大學生物醫學研究所 3Terry Fox癌症研究室 4國防醫學院臨床醫學研究所 5中國醫藥大學附設醫院泌尿外科 6彰化基督教醫院眼科部
The Relationship of Matrix Metalloproteinase-1 Promoter Polymorphisms with Prostate Cancer Patients in mid-Taiwan
Cheng-Hsi Liao1,2,3,4, Hsi-Chin Wu5, Wen-Shin Chang2,3, Chia-Wen Tsai2,3, Pei-Shin Hu3,6, and Da-Tian Bau2,3
1Division of Urology, Department of Surgery, Taichung Armed Forces General Hospital, Taichung, Taiwan, R.O.C.; 2Graduate Institute of Biomedical Science, China Medical University, Taichung, Taiwan, R.O.C.; 3Terry Fox Cancer Research Laboratory; 4Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei, Taiwan, R.O.C.; 5Department of Urology, China Medical University Hospital, Taichung, Taiwan, R.O.C.; 6Department of Ophthalmology, Changhua Christian hospital, Changhua, Taiwan, R.O.C.
Purpose: The family of matrix metallo-proteinases (MMPs) is responsible for the maintenance of extracellular matrix component homeostasis and the association of MMP-1 genetic polymorphisms with personal susceptibility to prostate cancer has only been investigated in Turkish and Japan populations and never in Taiwan. In the current study, we aimed to examine the contribution of a polymorphism in the promoter region of MMP-1 to Taiwan prostate cancer.
Materials and Methods: The MMP-1rs1799705 polymorphic genotypes were genotyped among 218prostate cancer patients and 436 healthy controls by the typical polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) methodology.
Results: The percentages of 2G/2G, 1G/2G, and 1G/1G for MMP-1 -1607genotypes were 36.2, 40.4 and 23.4% in the prostate cancer group and 33.7, 44.3, and 22.0% in the healthy control group(p trend=0.6362), respectively. The odds ratios (ORs) after adjusting for age and smoking status for those carrying 1G/2Gand 1G/1G genotypes at MMP-1 -1607 were 0.84(95%CI=0.55-1.21, p=0.3862) and 0.94 (95%CI=0.67-1.53,p=0.9586), respectively, compared to those carrying the wild type2G/2G genotype. Supporting these findings, the adjusted OR for those carrying the 1G allele at MMP-1 -1607 was 1.03 (95%CI=0.71-1.45, p=0.6910), compared to those carrying the wild-type 2G allele.
Conclusion:
Our findings suggest that the polymorphic genotypes at MMP-1 promoter -1607 may play a major role in determining personal cancer susceptibility for prostate cancer in Taiwan.